Display options
Cite
Veeraraghavan H, Vargas HA, Jimenez-Sanchez A, et al. Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113403.
Veeraraghavan, H., Vargas, H. A., Jimenez-Sanchez, A., Micco, M., Mema, E., Lakhman, Y., Crispin-Ortuzar, M., Huang, E. P., Levine, D. A., Grisham, R. N., Abu-Rustum, N., Deasy, J. O., Snyder, A., Miller, M. L., Brenton, J. D., & Sala, E. (2020). Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers, 12(11), . https://doi.org/10.3390/cancers12113403
Veeraraghavan, Harini, et al. "Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113403
Veeraraghavan H, Vargas HA, Jimenez-Sanchez A, Micco M, Mema E, Lakhman Y, Crispin-Ortuzar M, Huang EP, Levine DA, Grisham RN, Abu-Rustum N, Deasy JO, Snyder A, Miller ML, Brenton JD, Sala E. Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers (Basel). 2020 Nov 17;12(11). doi: 10.3390/cancers12113403. PMID: 33212885; PMCID: PMC7698381.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Nov 17;12(11). doi: 10.3390/cancers12113403.

Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma.

Cancers

Harini Veeraraghavan, Herbert Alberto Vargas, Alejandro Jimenez-Sanchez, Maura Micco, Eralda Mema, Yulia Lakhman, Mireia Crispin-Ortuzar, Erich P Huang, Douglas A Levine, Rachel N Grisham, Nadeem Abu-Rustum, Joseph O Deasy, Alexandra Snyder, Martin L Miller, James D Brenton, Evis Sala

Affiliations

  1. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  3. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, Cambridgeshire CB2 0RE, UK.
  4. Radioterapia Oncologica ed Ematologica, Dipartimento Diagnostica per Immagini, Area Diagnostica per Immagini, Radiologica Diagnostica e Interventistica Generale, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
  5. Columbia University Medical Center, New York, NY 10032, USA.
  6. National Cancer Institute, Rockville, MD 20850, USA.
  7. Laura and Issac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
  8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  9. Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
  10. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

PMID: 33212885 PMCID: PMC7698381 DOI: 10.3390/cancers12113403

[No abstract available.]

Keywords: chemotherapy response prognostication; computed tomography; high grade serous ovarian cancer; intra-site and inter-site radiomic heterogeneity; machine learning; radiomics

References

  1. J Stat Softw. 2010;33(1):1-22 - PubMed
  2. J Digit Imaging. 2013 Dec;26(6):1045-57 - PubMed
  3. Eur J Radiol. 2019 Apr;113:174-181 - PubMed
  4. Cell. 2017 Aug 24;170(5):927-938.e20 - PubMed
  5. Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6265-73 - PubMed
  6. Nat Commun. 2014 Jun 03;5:4006 - PubMed
  7. Cancer Res. 2019 Dec 15;79(24):6238-6246 - PubMed
  8. Phys Med Biol. 2019 Aug 21;64(16):165011 - PubMed
  9. Radiology. 2017 Nov;285(2):482-492 - PubMed
  10. United European Gastroenterol J. 2016 Apr;4(2):257-63 - PubMed
  11. NMR Biomed. 2014 Aug;27(8):887-96 - PubMed
  12. Magn Reson Imaging. 2012 Nov;30(9):1323-41 - PubMed
  13. Nature. 2011 Jun 29;474(7353):609-15 - PubMed
  14. PLoS Med. 2015 Feb 24;12(2):e1001789 - PubMed
  15. Radiology. 2018 Jan;286(1):307-315 - PubMed
  16. JCO Precis Oncol. 2019 Aug 15;3: - PubMed
  17. Radiology. 2015 Jul;276(1):313 - PubMed
  18. Nat Rev Cancer. 2015 Nov;15(11):668-79 - PubMed
  19. Stud Health Technol Inform. 2002;85:586-92 - PubMed
  20. CA Cancer J Clin. 2019 Jan;69(1):7-34 - PubMed
  21. Radiology. 2020 May;295(2):328-338 - PubMed
  22. Nat Genet. 2020 Jun;52(6):582-593 - PubMed
  23. Clin Cancer Res. 2020 Apr 15;26(8):1866-1876 - PubMed
  24. J Natl Cancer Inst. 2000 May 3;92(9):699-708 - PubMed
  25. Cell Syst. 2015 Dec 23;1(6):417-425 - PubMed
  26. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  27. Abdom Imaging. 2015 Oct;40(7):2331-7 - PubMed
  28. Radiology. 2015 Mar;274(3):742-51 - PubMed
  29. Nat Commun. 2019 Feb 15;10(1):764 - PubMed
  30. Eur Radiol. 2020 Aug;30(8):4306-4316 - PubMed
  31. Cell. 2018 Jun 14;173(7):1755-1769.e22 - PubMed
  32. Nature. 2009 Nov 5;462(7269):108-12 - PubMed
  33. BMC Bioinformatics. 2013 Jan 16;14:7 - PubMed
  34. Radiology. 2018 Jun;287(3):833-843 - PubMed
  35. Oncotarget. 2019 Jan 18;10(6):660-672 - PubMed
  36. J Pathol. 2013 Sep;231(1):21-34 - PubMed
  37. Eur Radiol. 2020 Jan;30(1):547-557 - PubMed
  38. Nat Biotechnol. 2007 Jun;25(6):675-80 - PubMed
  39. Nat Genet. 2016 Jul;48(7):758-67 - PubMed
  40. Cancer Biol Med. 2017 Feb;14(1):9-32 - PubMed
  41. Clin Radiol. 2017 Jan;72(1):3-10 - PubMed
  42. Int J Gynecol Cancer. 2011 May;21(4):771-5 - PubMed
  43. AJR Am J Roentgenol. 2015 Sep;205(3):W283-93 - PubMed
  44. Med Phys. 2018 Jun 13;: - PubMed
  45. Nat Commun. 2013;4:2612 - PubMed
  46. Eur Radiol. 2017 Sep;27(9):3991-4001 - PubMed
  47. Biometrics. 1988 Sep;44(3):837-45 - PubMed
  48. J Pathol. 2007 Feb;211(3):286-95 - PubMed
  49. Abdom Radiol (NY). 2019 Jun;44(6):2040-2047 - PubMed
  50. Oncotarget. 2018 Apr 13;9(28):20134-20155 - PubMed

Publication Types

Grant support